Alto Neuroscience
ANRO
77 hedge funds and large institutions have $95.3M invested in Alto Neuroscience in 2024 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 31 increasing their positions, 10 reducing their positions, and 22 closing their positions.
210% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 10
3% more funds holding
Funds holding: 75 → 77 (+2)
9% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 22
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.55% less ownership
Funds ownership: 85.09% → 83.54% (-1.5%)
48% less call options, than puts
Call options by funds: $136K | Put options by funds: $260K
64% less capital invested
Capital invested by funds: $265M → $95.3M (-$170M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$6.09M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$5.23M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.46M |
| 4 |
AC
Armistice Capital
New York
|
+$4.06M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$3.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$23.7M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$13.3M |
| 3 |
Jennison Associates
New York
|
-$9.52M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.85M |
| 5 |
PFMOSF
Philadelphia Financial Management of San Francisco
San Francisco,
California
|
-$5.15M |
ANRO Hedge Fund Activity: Q4 2024 in Review
77 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Alto Neuroscience (ANRO) for Q4 2024, worth a combined $95.3M — down 64% from $265M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ANRO positions and 22 closed out — a net gain of 2 holders — while 31 added to existing stakes and 10 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $6.09M. The largest seller was RA Capital Management, exiting entirely with an estimated $23.7M sold.
- 77 institutional investors held Alto Neuroscience (ANRO) as of Q4 2024, up from 75 in Q3 2024.
- Funds reported $95.3M of Alto Neuroscience stock for Q4 2024, down 64% quarter-over-quarter.
- 24 funds opened new Alto Neuroscience positions in Q4 2024 and 22 closed out, a net change of +2 holders.
- The largest Alto Neuroscience buyer in Q4 2024 was Citadel Advisors, an estimated $6.09M added.
- The largest Alto Neuroscience seller in Q4 2024 was RA Capital Management, an estimated $23.7M sold.
Based on aggregated 13F filings for Q4 2024.